Abdominal irradiation modulates 5-Fluorouracil pharmacokinetics

Journal of Translational Medicine

Volumn 8, Issue , 2010, Pages

  Hsieh, Chen Hsi ^a,b   Hsieh, Yen Ju ^a   Liu, Chia Yuan ^a,c   Tai, Hung Chi ^c   Huang, Yu Chuen ^e,f   Shueng, Pei Wei ^b,g   Wu, Le Jung ^b   Wang, Li Ying ^h   Tsai, Tung Hu ^a,d   Chen, Yu Jen ^a,c  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c MACKAY MEMORIAL HOSPITAL   (Taiwan)

^d TAIPEI CITY HOSPITAL   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^h NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC ANTIMETABOLITE;

ABDOMINAL RADIOTHERAPY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; HUMAN; NONHUMAN; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RAT; TOMOTHERAPY; ABDOMINAL TUMOR; ANIMAL; BILE DUCT CARCINOMA; DOSE RESPONSE; DRUG EFFECT; LIVER; MALE; METABOLISM; MULTIMODALITY CANCER THERAPY; RADIATION EXPOSURE; RADIATION RESPONSE; SPRAGUE DAWLEY RAT;

ABDOMINAL NEOPLASMS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; FLUOROURACIL; HUMANS; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77952302042     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-8-29     Document Type: Article

References (31)

1. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol 2006, 78:236-244. 10.1016/j.radonc.2006.01.009, 16545878.
2. Kim S, Kim SW, Bang YJ, Heo DS, Ha SW. Role of postoperative radiotherapy in the management of extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 2002, 54:414-419.
3. Moertel CG, Frytak S, Hahn RG, O'Connell MJ, Reitemeier RJ, Rubin J, Schutt AJ, Weiland LH, Childs DS, Holbrook MA, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981, 48:1705-1710. 10.1002/1097-0142(19811015)48:8<1705::AID-CNCR2820480803>3.0.CO;2-4, 7284971.
4. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730. 10.1056/NEJMoa010187, 11547741.
5. Krook JE, Moertel CG, Gunderson LL, Wieand HS, Collins RT, Beart RW, Kubista TP, Poon MA, Meyers WC, Mailliard JA, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991, 324:709-715.
6. Poortmans PM, Richaud P, Collette L, Ho Goey S, Pierart M, Hulst M, Bolla M. Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder. Acta Oncol 2008, 47:937-940. 10.1080/02841860801888799, 18568488.
7. Is there a need for more precise definitions of bioavailability? Conclusions of a consensus workshop, Munich, September 9, 1989; under the patronage of the F.I.P. Eur J Clin Pharmacol 1991, 40:123-126. 10.1007/BF01418409, 2065692.
8. Di Paolo A, Lencioni M, Amatori F, Di Donato S, Bocci G, Orlandini C, Lastella M, Federici F, Iannopollo M, Falcone A, et al. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer. Clin Cancer Res 2008, 14:2749-2755. 10.1158/1078-0432.CCR-07-1529, 18451241.
9. Verhey LJ. Comparison of three-dimensional conformal radiation therapy and intensity-modulated radiation therapy systems. Semin Radiat Oncol 1999, 9:78-98. 10.1016/S1053-4296(99)80056-3, 10196400.
10. Shueng PW, Lin SC, Chong NS, Lee HY, Tien HJ, Wu LJ, Chen CA, Lee JJ, Hsieh CH. Total marrow irradiation with helical tomotherapy for bone marrow transplantation of multiple myeloma: first experience in Asia. Technol Cancer Res Treat 2009, 8:29-38.
11. Chao KS, Low DA, Perez CA, Purdy JA. Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer 2000, 90:92-103. 10.1002/(SICI)1097-0215(20000420)90:2<92::AID-IJC5>3.0.CO;2-9, 10814959.
12. Tai HC, Hsieh CH, Chao KS, Liu SH, Leu YS, Chang YF, Hsiao HT, Chang YC, Huang DY, Chen YJ. Comparison of radiotherapy strategies for locally advanced hypopharyngeal cancer after resection and ileocolic flap reconstruction. Acta Otolaryngol 2009, 129:311-317. 10.1080/00016480802163366, 18607975.
13. Vriesendorp HM, Van Bekkum DW. Susceptibility to total-body irradiaiton. Response to Total-Body Irradiation in Different Species 1984, Amsterdam: Martinus Nijhoff, Broerse JJ, T M.
14. Ambre JJ, Fischer LJ. The effect of prednisolone and other factors on the catabolism of 5-fluorouracil in rats. J Lab Clin Med 1971, 78:343-353.
15. Jarugula VR, Lam SS, Boudinot FD. Nonlinear pharmacokinetics of 5-fluorouracil in rats. J Pharm Sci 1997, 86:756-758. 10.1021/js960451a, 9188061.
16. Bocci G, Danesi R, Di Paolo AD, Innocenti F, Allegrini G, Falcone A, Melosi A, Battistoni M, Barsanti G, Conte PF, Del Tacca M. Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. Clin Cancer Res 2000, 6:3032-3037.
17. Casale F, Canaparo R, Serpe L, Muntoni E, Pepa CD, Costa M, Mairone L, Zara GP, Fornari G, Eandi M. Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. Pharmacol Res 2004, 50:173-179. 10.1016/j.phrs.2004.01.006, 15177306.
18. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993, 53:5433-5438.
19. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47:2203-2206.
20. Gamelin E, Boisdron-Celle M. Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art. Crit Rev Oncol Hematol 1999, 30:71-79. 10.1016/S1040-8428(98)00036-5, 10439055.
21. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 1994, 12:2239-2242.
22. Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 1999, 79:627-630. 10.1038/sj.bjc.6690098, 2362417, 10027340.
23. Deeken JF, Figg WD, Bates SE, Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007, 18:111-126. 10.1097/CAD.0b013e3280109411, 17159598.
24. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004, 40:939-950. 10.1016/j.ejca.2003.12.004, 15093568.
25. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest 1996, 98:610-615. 10.1172/JCI118830, 507468, 8698850.
26. Peters GJ. Antimetabolites. Oxford Textbook of Oncology 1995, 524-552. London: Oxford University Press, Peckam M, Pinedo HM, Veronesi U.
27. Gusella M, Rebeschini M, Cartei G, Ferrazzi E, Ferrari M, Padrini R. Effect of hemodialysis on the metabolic clearance of 5-Fluorouracil in a patient with end-stage renal failure. Ther Drug Monit 2005, 27:816-818. 10.1097/01.ftd.0000183384.89275.f4, 16306860.
28. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin LJ, Wesson M. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.
29. Geraci JP, Mariano MS, Jackson KL. Radiation hepatology of the rat: time-dependent recovery. Radiat Res 1993, 136:214-221. 10.2307/3578613, 8248478.
30. Geraci JP, Mariano MS, Jackson KL. Hepatic radiation injury in the rat. Radiat Res 1991, 125:65-72. 10.2307/3577983, 1824725.
31. Sharma M, Halligan BD, Wakim BT, Savin VJ, Cohen EP, Moulder JE. The Urine Proteome as a Biomarker of Radiation Injury: Submitted to Proteomics- Clinical Applications Special Issue: "Renal and Urinary Proteomics (Thongboonkerd)". Proteomics Clin Appl 2008, 2:1065-1086. 10.1002/prca.200780153, 2739391, 19746194.